1. Introduction {#sec1}
===============

Systemic capillary leak syndrome (SCLS) is a rare but fatal condition characterized by severe hypotension, hypoalbuminemia, and hemoconcentration \[[@B1], [@B2]\]. These characteristic symptoms are thought to be caused by excessive vascular permeability due to vascular endothelial dysfunction and leakage of a large amount of plasma component from the blood vessel \[[@B2]\]. Although monoclonal proteinemia is present in about 80% of SCLS \[[@B3]\] and a large number of mediators that promote vascular permeability \[[@B4]\] have been reported, the pathogenesis of SCLS is unknown.

According to these hypotheses, various treatments targeting correction of vascular permeability have been attempted \[[@B5]--[@B7]\]. To date, treatment with vascular endothelial cell growth factor (VEGF) inhibitor \[[@B5]\], tumor necrosis factor (TNF)-*α* inhibitor \[[@B6]\], and thalidomide \[[@B7]\] has been attempted, but these have not been widely used. It has been sporadically reported that high-dose intravenous immunoglobulin (IVIG) therapy is effective in some cases of SCLS \[[@B8]--[@B10]\]; however, the mechanism of its efficacy is also still unknown.

As for SCLS associated with connective tissue disease (CTD), not only is it rarely encountered in clinical practice, but also there are very few reports \[[@B11]--[@B15]\] about it. Because of little information on the treatment strategy for SCLS associated with CTD, it is difficult to draw a conclusion on which therapy should be performed: treatment against SCLS as a vascular event or underlying disease using immunosuppressive agents.

We encountered Sjögren\'s syndrome (SS) that showed SCLS-like symptoms, from the finding of massive thoracoabdominal fluid and systemic edema with hypoalbuminemia and hematocrit (Ht) level elevation. Repeated episodes wherein combination treatment with glucocorticoid (GC) and IVIG was effective, despite the inefficacy of their monotherapy, may provide a clue on the pathophysiology and treatment strategy of SCLS associated with CTD.

2. Case Presentation {#sec2}
====================

A 70-year-old woman complained of systemic edema and excessive weight gain. Since she has hypertension and a history of subarachnoid hemorrhage at the age of 50 years, she had taken antihypertensive agents, including amlodipine besylate and candesartan cilexetil. In year X-25, she was diagnosed with SS because of dry eyes confirmed by the Schirmer and Rose Bengal test, mononuclear cell infiltration around the salivary gland, and the presence of anti-SSA antibodies. In July of year X-1, she visited our hospital due to body weight gain of 3 kg in a month, lower leg edema, and dyspnea. Computed tomography (CT) showed thoracoabdominal fluid. She was admitted in September.

Upon admission, she had normal blood pressure of 119/83 mmHg, and oxygen saturation was 97%. She had no cardiac murmurs. Her respiratory sound attenuates in both lower lungs and marked subcutaneous edema in the abdomen and legs was noted.

Laboratory findings revealed elevated Ht level of 45.6%, with lower total protein (TP) (6.1 g/dL) and albumin (ALB) levels (2.9 g/dL) ([Table 1](#tab1){ref-type="table"}). Thyroid function was normal. Antinuclear antibody showing a centromeric pattern and anti-SSA antibody were positive. Serum M and urinary Bence Jones proteins were not detected. CT showed moderate pleural effusion and ascites. Echocardiography showed small amount of pericardial effusion, no ventricle expansion with normal tricuspid valve systolic pressure gradient, and normal diameter of the inferior vena cava with respiratory fluctuation, indicating that her cardiac function was normal.

At first, we considered the thoracoabdominal fluid as serositis with SS and started celecoxib 400 mg/day ([Figure 1](#fig1){ref-type="fig"}). However, pleural effusion did not decrease, and body weight still increased. Prednisolone (PSL) 35 mg/day (0.5 mg/kg/day) was started, and body weight gradually decreased; however, difficulty in breathing, subcutaneous edema, and pleural effusion worsened. In addition, hypoalbuminemia worsened, and the Ht level continued to increase. Other causes resembling SCLS, i.e., angioedema, monoclonal gammopathy of undetermined significance, and CTD other than SS, were distinguished by her clinical history, physical, and laboratory findings. We decided to treat the condition as chronic SCLS, administering terbutaline 6 mg/day and theophylline 300 mg/day starting that day. However, they were ineffective, and hypoalbuminemia progressed. Therefore, 35 g/day (0.4 g/kg/day) of IVIG was administered for 5 days from hospital day 31, in addition to 30 mg/day of PSL. After three days, the Ht level decreased and hypoalbuminemia began to improve. Subcutaneous edema and pleural effusion also improved, and she was discharged.

After discharge, the dose of PSL was gradually decreased. However, after decreasing the PSL dose to 2 mg/day in March of year X, abdominal fullness was noted. Subcutaneous edema and pleural effusion redeveloped and worsened. In May of year X, she had difficulty in breathing and was rehospitalized.

Upon admission, her blood pressure was 102/60 mmHg, and severe abdominal edema was observed. Hemoconcentration, hypoalbuminemia, and thoracoabdominal fluid, as in the previous condition, were also present.

She was diagnosed with relapse of chronic SCLS, and 35 g/day (0.4 g/kg/day) of IVIG was started without increasing the PSL dose because her clinical history suggested that only IVIG might be essential. However, severe abdominal edema did not improve even after 5 days of IVIG therapy. We thought that IVIG alone seemed ineffective. Because the difficulty in breathing worsened, PSL dose was increased to 35 mg/day (0.5 mg/kg/day). Subsequently, shortness of breath, abdominal edema, and thoracoabdominal fluid improved. Hypoalbuminemia also improved. She was then successfully discharged.

3. Discussion {#sec3}
=============

This is a rare case of chronic SCLS complicated with SS. Regarding her treatment course, it seems that the combination therapy of moderate dose of PSL and IVIG was effective.

Severe edema and massive thoracoabdominal fluid in this case were considered to be involved in the same mechanism as chronic SCLS. In this case, hypovolemic shock, one of three signs of SCLS, was lacking. However, those symptoms accompanied by hypoproteinemia and hypoalbuminemia indicated excessive vascular permeability with concomitant leakage of plasma components into the extravascular tissue. In addition, repeated similar episodes were also consistent with SCLS \[[@B1]\]. While a typical SCLS \[[@B16]\] rapidly causes systemic edema, hypotension, hemoconcentration, and compartment syndrome, cases of chronic SCLS \[[@B17]\] have been reported recently. These cases were characterized by gradual excessive weight gain and systemic edema. Because this case showed a similar course as that in chronic SCLS, chronic SCLS was mostly considered.

IVIG has been thought to be an effective treatment for SCLS. Various treatments such as VEGF inhibitor \[[@B5]\], TNF-*α* inhibitor \[[@B6]\], and thalidomide \[[@B7]\] have been attempted to correct vascular hyperpermeability, which is considered as a main pathology of SCLS. However, these agents were not widely used. Meanwhile, some reports showed efficacy of IVIG for SCLS \[[@B8]--[@B10]\]. Lambert \[[@B8]\] reported that the 5-year survival rate of the IVIG-treated group was 93.8% and that of the non-IVIG group was 67.2%. In a report by Gousseff \[[@B9]\], 4 of 5 patients in the non-IVIG group died, whereas only 1 of 4 patients in the IVIG-treated group died. Therefore, IVIG might be effective for SCLS.

It is sporadically reported that SCLS is also complicated with CTD \[[@B11]--[@B15]\]. However, in these cases, GC rather than IVIG was effective, which is different from typical SCLS. As shown in [Table 2](#tab2){ref-type="table"}, SCLS or localized capillary leak syndrome are complicated with SS \[[@B11]\], scleroderma \[[@B11]--[@B13]\], polymyositis \[[@B11]\], juvenile dermatomyositis (JDM) \[[@B14]\], and systemic lupus erythematosus (SLE) \[[@B15]\]. In SCLS with CTD, there are 4 treatment patterns: immunosuppressant including GC only (cases 5, 6, 11, and 12), IVIG for GC resistance (case 1), IVIG only (cases 3, 8, 9, and 10), and others (case 2, 7). Although GC seems effective for SCLS with SLE, IVIG is needed for JDM. In contrast, in SCLS with SS, efficacy of GC or IVIG seems different in each case. However, unlike idiopathic SCLS, it could be said that there are SCLS cases with CTD in which GC, not IVIG, showed efficacy.

Anticentromere antibody (ACA) and anti-SSA antibody double-positive SS patients are reported to have higher disease activity \[[@B18]\]. Although the volume of pleural effusion fluctuated, symptoms other than SCLS were not seen during the treatment course, suggesting that SCLS is not related to disease activity of SS in this case. As for anti-SSA antibody, anti-SSA antibody-positive CTD cases with SCLS were reported \[[@B11], [@B15]\]. Moreover, in the mouse model, anti-Ro 52 antibody has potential to cause salivary gland dysfunction via innate immunity \[[@B19]\]. These facts suggest that anti-SSA antibody might be associated with pathology of SCLS.

In the present case, monotherapy of IVIG or GC was ineffective, but the combined use of both was effective. In the first admission, thoracoabdominal fluid did not decrease with administration of 35 mg/day of PSL, and concomitant use of IVIG was successful. In the second admission, IVIG without increasing the PSL dose did not decrease the thoracoabdominal fluid, but the thoracoabdominal fluid improved after increasing the PSL dose to 35 mg/day when the amount of immunoglobulins seemed to remain in the body. These facts might suggest that not only combination therapy is effective but also the action mechanism of IVIG might be different from that of GC in SCLS with CTD. Otherwise, the pathogenesis of SCLS with CTD may be different from that without CTD.

We reported on SS complicated with SCLS-like symptoms, which was successfully treated with a combination of IVIG and GC. In the case of SCLS with CTD, even if monotherapy of IVIG or GC is ineffective, their combination might be effective. Combination therapy with GC and IVIG should be taken into consideration.
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![Clinical course of the present case. ALB: albumin; Ht: hematocrit; IVIG: intravenous immunoglobulin; PSL: predonisolone.](CRIRH2019-4865024.001){#fig1}

###### 

Laboratory data on first admission.

  Peripheral blood   Biochemistry         Immunological test                                         
  ------------------ -------------------- --------------------- --------------- -------------------- ------------
  WBC                7480 mm^3^           Total protein         6.1 g/dL        IgG                  982 mg/dL
  Neutrophil         55%                  Albumin               2.9 g/dL        IgA                  257 mg/dL
  Lymphocyte         29.5%                AST                   23 U/L          IgM                  241 mg/dL
  Monocyte           6.6%                 ALT                   14 U/L          ANA                   
  Eosinophil         8%                   LDH                   176 U/L         Centromere pattern   ×640
  Basophil           0.9%                 *γ*-GTP               42 U/L          Anti-SSA antibody    48.2 U/mL
  Red blood cell     508 × 10^4^ mm^3^    Blood urea nitrogen   9.2 mg/dL       Anti-SSB antibody    \<0.5 U/mL
  Hb                 14.9 g/dL            Creatinine            0.71 mg/dL      Pleural effusion      
  Hematocrit         45.6%                C-reactive protein    0.11 mg/dL      WBC                  470 mm^3^
  MCV                90 fL                Endocrine                             Mononuclear cell     92.2%
  Platelet           30.4 × 10^4^ mm^3^   TSH                   2.48 *µ*IU/mL   Polynuclear cell     7.8%
  FT3                3 pg/mL              Total protein         3.6 g/dL                             
  FT4                1.3 ng/dL            LDH                   108 U/L                              

MCV: mean corpuscular volume; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH: lactate dehydrogenase; *γ*-GTP: *γ*-glutamyl transpeptidase; TSH: thyroid-stimulating hormone; FT3: free triiodothyronine; FT4: free thyroxine; ANA: antinuclear antibody.

###### 

Characteristics of SCSL with CTD.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case            Age   Gender   CTD   Treatments before SCLS   Symptoms and/or laboratory findings at the onset of SCLS                        Anti-SSA antibody   Treatments for SCLS          Outcome
  --------------- ----- -------- ----- ------------------------ ------------------------------------------------------------------------------- ------------------- ---------------------------- -----------
  1 \[[@B11]\]    25    F        SS    GC                       Abdominal pain, nausea, vomiting pericardial effusion, ascites                  Positive            GC and diuretics-IVIG        Remission

  2 \[[@B11]\]    43    M        SS\   D-pen                    Weight gain, hemoconcentration hypoalbuminemia                                  Negative            Diuretics and IVIG           Dead
                                 SSc                                                                                                                                                             

  3 \[[@B11]\]    17    M        PM    GC, MTX, AZA             Edema of upper limbs and face, hemoconcentration, hypoalbuminemia               Negative            IVIG                         Remission

  4 \[[@B11]\]    45    F        SS    None                     Oliguria, loss of weight hemoconcentration, hypoalbuminemia                     Positive            Transfusion and IVIG         Remission

  5 \[[@B11]\]    55    F        SS    None                     Hypovolemic shock hemoconcentration, hypoproteinemia                            Positive            Transfusion and GC           Remission

  6 \[[@B12]\]    61    M        SSc   None                     Shortness of breath, profuse sweating, leg edema, severe fatigue, and otalgia   NA                  High-dose GC and diuretics   Remission

  7 \[[@B13]\]    52    F        SSc   Imatinib mesylate        Facial and lower extremity edema, and elevated alkaline phosphatase             NA                  Vasopressor                  Dead

  8 \[[@B14]\]    7     M        JDM   GC pulse high-dose GC    Edema of the neck and upper limbs, myalgia, oliguria, and hypotension           NA                  IVIG                         Remission

  9 \[[@B14]\]    13    M        JDM   GC pulse                 Generalized edema, myalgia, oliguria, hypotension, and tachycardia              NA                  IVIG                         Remission

  10 \[[@B14]\]   3     M        JDM   GC pulse high-dose GC    Edema of the face and neck, oliguria, acute kidney, and respiratory failure     NA                  IVIG                         Remission

  11 \[[@B15]\]   40    F        SLE   GC CPA, AZA              Nausea, vomiting, and intestinal wall edema at CT scan                          NA                  Transfusion and IS           Remission

  12 \[[@B15]\]   41    F        SLE   GC HCQ                   Nausea, vomiting, and intestinal wall edema at CT scan                          Positive            High-dose GC                 Remission
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

F: female; M: male; NA: not available; SCLS: systemic capillary leak syndrome; CTD: connective tissue disease; SS: Sjögren\'s syndrome; SSc: systemic sclerosis; PM: polymyositis; JDM: juvenile dermatomyositis; SLE: systemic lupus erythematosus; GC: glucocorticoid; IVIG: intravenous immunoglobulin therapy; D-pen: D-penicillamine; AZA: azathioprine; CPA: cyclophosphamide; HCQ: hydroxychloroquine; MMF: mycophenolate mofetil.
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